Wednesday, October 21, 2020 Landmark TB Trial Identifies Shorter-Course Treatment Regimen A large international clinical trial has found that a new four-month daily treatment regimen is as safe and effective as the standard six-month daily regimen at curing drug-susceptible tuberculosis (TB) disease. A shorter regimen has the potential to increase completion of therapy, improve patient quality of life, reduce treatment costs, and decrease development of drug resistance. Results from the Phase 3 trial, which was led by the CDC's Tuberculosis Trials Consortium with collaboration from the NIAID-funded AIDS Clinical Trials Group, will help inform future TB treatment. The findings were presented today at the virtual Union World Conference on Lung Health.  National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107